Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

Nature Reviews Clinical Oncology, Published online: 08 January 2024; doi:10.1038/s41571-023-00849-9The discovery of ERBB2 as a gene frequently amplified and/or overexpressed in breast cancers and of its product HER2 as a biomarker has spurred the development of various targeted therapies. As a result, the prognosis of patients with advanced-stage HER2-positive breast cancer has greatly improved in the past decades. The authors of this Review describe the development of the current treatment landscape for these patients and discuss how to address resistance to further improve outcomes.

Source: Nature Reviews Clinical Oncology - January 8, 2024 Category: Cancer & Oncology Authors: Antonio Marra Sarat Chandarlapaty Shanu Modi Source Type: research